Literature DB >> 16584786

Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids.

Murat Oz1.   

Abstract

Cannabinoids are a structurally diverse group of mostly lipophilic molecules that bind to cannabinoid receptors. In fact, endogenous cannabinoids (endocannabinoids) are a class of signaling lipids consisting of amides and esters of long-chain polyunsaturated fatty acids. They are synthesized from lipid precursors in plasma membranes via Ca(2+) or G-protein-dependent processes and exhibit cannabinoid-like actions by binding to cannabinoid receptors. However, endocannabinoids can produce effects that are not mediated by these receptors. In pharmacologically relevant concentrations, endocannabinoids modulate the functional properties of voltage-gated ion channels including Ca(2+) channels, Na(+) channels, various types of K(+) channels, and ligand-gated ion channels such as serotonin type 3, nicotinic acetylcholine, and glycine receptors. In addition, modulatory effects of endocannabinoids on other ion-transporting membrane proteins such as transient potential receptor-class channels, gap junctions and transporters for neurotransmitters have also been demonstrated. Furthermore, functional properties of G-protein-coupled receptors for different types of neurotransmitters and neuropeptides are altered by direct actions of endocannabinoids. Although the mechanisms of these effects are currently not clear, it is likely that these direct actions of endocannabinoids are due to their lipophilic structures. These findings indicate that additional molecular targets for endocannabinoids exist and that these targets may represent novel sites for cannabinoids to alter either the excitability of the neurons or the response of the neuronal systems. This review focuses on the results of recent studies indicating that beyond their receptor-mediated effects, endocannabinoids alter the functions of ion channels and other integral membrane proteins directly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584786     DOI: 10.1016/j.pharmthera.2005.09.009

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  50 in total

Review 1.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling.

Authors:  Stephanie C Gantz; Bruce P Bean
Journal:  Neuron       Date:  2017-03-02       Impact factor: 17.173

Review 3.  Endocannabinoid liberation from neurons in transsynaptic signaling.

Authors:  David M Lovinger
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

Review 4.  Allosteric modulation of glycine receptors.

Authors:  Gonzalo E Yevenes; Hanns Ulrich Zeilhofer
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  5,6-EET potently inhibits T-type calcium channels: implication in the regulation of the vascular tone.

Authors:  Magali Cazade; Isabelle Bidaud; Pernille B Hansen; Philippe Lory; Jean Chemin
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

6.  Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.

Authors:  Anna Pędzińska-Betiuk; Jolanta Weresa; Marek Toczek; Marta Baranowska-Kuczko; Irena Kasacka; Ewa Harasim-Symbor; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

7.  Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol.

Authors:  Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

Review 10.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.